57653-35-7

Upstream product

• 67-56-1 methanol 
• 80986-14-7 5-aza-5-carbobenzoxy-2-oxa-3-oxo-bicyclo<2.2.1>heptane 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 
• 618-27-9 hydroxy L-proline 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 501-53-1 benzyl chloroformate 
• 1527519-52-3 (2S,4S)-1-benzyl 2-methyl 4-(benzoyloxy)pyrrolidine-1,2-dicarboxylate 
• 117811-78-6 methyl (2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylate 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 51-35-4 4R-4-hydroxyproline 
• 13500-53-3 N-benzyloxycarbonyl-(2S,4R)-4-hydroxyproline benzyl ester 
• 13504-86-4 (2S,4S)-1-benzyloxycarbonyl-4-hydroxyproline 
• 16217-15-5 1-benzyloxycarbonyl-4-oxo-L-proline methyl ester 
• 186581-53-3 diazomethane 

Downstream Products

• 556834-89-0 1-benzyl 2-methyl (2S)-4-fluoropyrrolidine-1,2-dicarboxylate 
• 1035596-36-1 (2S,4R)-1-benzyl 2-methyl 4-(1,3-dioxoisoindolin-2-yl)pyrrolidine-1,2-dicarboxylate 
• 279-33-4 (1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]heptane 
• 16217-15-5 1-benzyloxycarbonyl-4-oxo-L-proline methyl ester 
• 16217-17-7 7-<(phenylmethoxy)carbonyl>-1,4-dioxa-7-azaspiro<4,4>-nonane-8(S)-carboxylic acid methyl ester 
• 1256390-39-2 (S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]nonane-8-carboxylic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester 
• 1256390-26-7 methyl ((S)-1-((S)-8-(5-(4-bromophenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1399843-64-1 methyl ((S)-3-methyl-1-oxo-1-((S)-8-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)butan-2-yl)carbamate 
• 117653-45-9 (1R,5R)-4-((1R,2S)-1-Carboxy-2-methyl-butylamino)-3-cyano-6-aza-bicyclo[3.2.1]oct-3-ene-6-carboxylic acid benzyl ester 
• 117653-45-9 (1S,5S)-4-((1S,2S)-1-Carboxy-2-methyl-butylamino)-3-cyano-6-aza-bicyclo[3.2.1]oct-3-ene-6-carboxylic acid benzyl ester 
• 115545-81-8 4-(1-tert-Butoxycarbonyl-ethylamino)-3-cyano-6-aza-bicyclo[3.2.1]oct-3-ene-6-carboxylic acid benzyl ester 
• 115545-80-7 methyl N-<4-<6-(benzyloxycarbonyl)-3-cyano-6-azabicyclo<3.2.1>oct-2-enyl>>-L-alaninate 
• 115545-76-1 6-(benzyloxycarbonyl)-3-cyano-4-keto-6-azabicyclo<3.2.1>octane 
• 115545-79-4 6-(benzyloxycarbonyl)-3-cyano-4-chloro-6-azabicyclo<3.2.1>oct-3-ene 

Relevant academic research and scientific papers

ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

ROR [gamma]t inhibitor, preparation method and application thereof

The invention relates to the technical field of medicines, in particular to an ROR [gamma]t inhibitor, a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound, a method for preparing the pharmaceutical composition, and application of the compound or the pharmaceutical composition in treatment or prevention of ROR [gamma]t-mediated cancers, inflammations or autoimmune diseases of mammals, especially human beings.

Five-membered heteroaromatic derivative, preparation method and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a five-membered heteroaromatic compound, a composition, a preparation method and application thereof. The compound or the composition can be used as an inhibitor of a retinoid-related orphan receptor [gamma]t (ROR [gamma]t). The invention also relates to a method for preparing the compound and the composition, and application of the compound and the composition in treatment or prevention of ROR [gamma]t-mediated cancers, inflammations or autoimmune diseases of mammals, especially human beings.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.

HYDROXYPROLINE DERIVATIVE

PROBLEM TO BE SOLVED: To provide hydroxyproline derivatives useful as catalysts for e.g. Michael addition reactions and their salts. SOLUTION: Hydroxyproline derivatives having a relative configuration of formula (I) and their salts are provided. In formu

FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X', Y, Y', A, A',Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.

PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to phenyl amino pyrimidine bicyclic compounds formula (I) which are inhibitors of protein kinases including JAK kinases. In particular the compounds are active against JAK1, JAK2, JAK3 and TYK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

L-proline-catalyzed asymmetric michael addition of 2-oxindoles to enones: A convenient access to oxindoles with a quaternary stereocenter

A new organocatalytic approach for 1,4-conjugate addition of 2-oxindoles to α,β-unsaturated ketones using the combination of readily available and nonexpensive l-proline and achiral trans-2,5-dimethylpiperazine as catalytic system is provided. The reaction results in oxindole derivatives with vicinal quaternary and tertiary carbon centers in up to 99% yield and 91% ee. Georg Thieme Verlag Stuttgart.